Loading...

Purified anti-mouse CD11c Antibody

Pricing & Availability
Clone
N418 (See other available formats)
Regulatory Status
RUO
Other Names
αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
N418_A_Purified_Pos_071006.jpg
C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and purified N418 (top) or purified Armenian hamster IgG isotype control (bottom), followed by anti-Armenian hamster IgG FITC
  • N418_A_Purified_Pos_071006.jpg
    C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and purified N418 (top) or purified Armenian hamster IgG isotype control (bottom), followed by anti-Armenian hamster IgG FITC
  • N418_B_Purified_Neg_071006.jpg
Compare all formats
Cat # Size Price Quantity Check Availability Save
117301 50 µg 29€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
117302 500 µg 113€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse spleen dendritic cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
IP, IHC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation3, immunohistochemical staining of acetone-fixed frozen sections3, immunofluorescence microscopy5, 9 (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections10), and spatial biology (IBEX)22,23.

Application References
  1. Granucci F, et al. 1997. J. Immunol. 159:1794.
  2. Stokes RW, et al. 1998. J. Immunol. 160:5514.
  3. Metlay JP, et al. 1990. J. Exp. Med. 171:1753. (IHC, IP)
  4. Ma XT, et al. 2006. Cancer Research 66:1169.
  5. Chin RK, et al. 2006. J. Immunol. 177:290. (IF)
  6. Cervantes-Barragan L, et al. 2007. Blood 109:1131. (FC) PubMed
  7. Turnquist HR, et al. 2007. J. Immunol. 178:7018. (FC) PubMed
  8. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  9. You Y, et al. 2009. J. Immunol. 182:7343. (IF) PubMed
  10. Roland CL, et al. 2009. Mol. Cancer Res. 8:1761. (IHC, FC) PubMed
  11. Wikstrom M, et al.2006. J. Immunol. 177:913. PubMed
  12. Pericolini E, et al. 2008. J. Leukocyte Biol. 83:1286. PubMed
  13. Randall LM, et al. 2008. Infect. Immun.76:3312. PubMed
  14. Fahlen-Yrild L, et al. 2009. J. Immunol. 183:5032. PubMed
  15. Osterholzer JJ, et al. 2009. J. Immunol. 183:8044. PubMed
  16. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  17. Eisenach PA, et al. 2010. J Cell Sci. 123:4182. PubMed
  18. Leppin K, et al. 2014. Invest. Ophthalmol. Vis. Sci. 55:3603. PubMed
  19. Sakai F, et al. 2014. PLoS One. 9:105370. PubMed
  20. Gibbins JD, et al. 2014. Blood. 124:2953. PubMed
  21. White CE, et al. 2015. J Immunol. 194:697. PubMed
  22. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  23. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  24. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Hernández-Santana YE, et al. 2020. Life Sci Alliance. 3:00. PubMed
  2. Martinez LE, et al. 2020. J Virol. 94:00:00. PubMed
  3. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  4. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  5. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  6. Aguilar EG, et al. 2021. Blood Adv. 5:4219. PubMed
  7. Owen KL, et al. 2020. EMBO Rep. 21:e50162. PubMed
  8. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  9. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  10. Bruce DW, et al. 2021. Blood Adv. 5:4578. PubMed
  11. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  12. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  13. Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed
  14. Blériot C, et al. 2020. Methods Mol Biol. 2164:87. PubMed
  15. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  16. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  17. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  18. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  19. Liedmann S, et al. 2022. Mol Cell. 82:2401. PubMed
  20. Campisi L, et al. 2022. Nature. 606:945. PubMed
  21. Chi H, et al. 2022. Cells. 11: . PubMed
  22. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  23. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  24. Hezaveh K, et al. 2022. Immunity. 55:324. PubMed
  25. Chen W, et al. 2023. JCI Insight. 8:. PubMed
  26. Iguchi A, et al. 2023. iScience. 26:106375. PubMed
  27. Xu J, et al. 2023. Discov Oncol. 14:68. PubMed
  28. Mendes A, et al. 2021. Life Sci Alliance. 4:00. PubMed
  29. Fahlén-Yrlid L, et al. 2009. J Immunol. 183:5032. PubMed
  30. Osterholzer J, et al. 2009. J Immunol. 183:8044. PubMed
  31. Sun L, et al. 2020. Nat Commun. 2.229166667. PubMed
  32. Trittel S, et al. 2019. Sci Rep. 9:16362. PubMed
  33. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  34. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  35. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  36. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  37. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  38. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  39. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
  40. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  41. Dubrot J, et al. 2018. Life Sci Alliance. 1:e201800164. PubMed
  42. Field CS, et al. 2018. Oncoimmunology. 7:e1376154. PubMed
  43. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  44. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  45. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
  46. Fang C, et al. 2020. Cell Mol Immunol. . PubMed
  47. Bonnefoy F, et al. 2018. Front Immunol. 2.170833333. PubMed
  48. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
  49. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  50. Lechner AJ et al. 2017. Cell stem cell. 21(1):120-134 . PubMed
  51. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  52. Tal MC, et al. 2020. MBio. 11:00. PubMed
  53. Hitchcock JR, et al. 2020. FEBS J. 287:250. PubMed
  54. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  55. Kitai Y, et al. 2017. J Immunol. 198:1649. PubMed
  56. Sutton C, et al. 2017. Nat Commun.. 10.1038/s41467-017-02111-0. PubMed
  57. Lee JH, et al. 2022. iScience. 25:104166. PubMed
  58. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  59. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  60. Delgobo M, et al. 2021. Front Immunol. 12:584538. PubMed
  61. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  62. Aparicio-Domingo P, et al. 2015. J Exp Med. 101084/jm20150318. PubMed
  63. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  64. Nolin JD, et al. 2017. JCI Insight. 2:e94929. PubMed
  65. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
  66. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  67. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  68. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  69. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  70. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  71. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  72. Manni M, et al. 2018. Nat Immunol. 1.074305556. PubMed
  73. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  74. Fu H, et al. 2019. Front Immunol. 10:271. PubMed
  75. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  76. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  77. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  78. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  79. Molica F,et al. 2017. Sci Rep.. 10.1038/s41598-017-14130-4. PubMed
  80. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  81. Mainini F, et al. 2018. Nucleic Acid Ther. 28:225. PubMed
  82. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  83. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  84. Wang Y, et al. 2021. Sci Transl Med. 13:. PubMed
  85. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  86. Wei S, et al. 2019. Virulence. 0.588888889. PubMed
  87. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  88. Borges TJ, et al. 2018. Nat Commun. 9:3482. PubMed
  89. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  90. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  91. Nascimento DC, et al. 2017. Nat Commun. 8:14919. PubMed
  92. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  93. Majer O, et al. 2019. Nature. 575:366. PubMed
  94. Pericolini E, et al. 2008. J Leukoc Biol. 83:1286. PubMed
  95. Johnson SA, et al. 2021. Eur J Immunol. 51:3228. PubMed
  96. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  97. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  98. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  99. Blriot C, et al. 2021. Immunity. :. PubMed
  100. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  101. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  102. King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed
  103. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  104. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  105. Oyarce K, et al. 2018. Front Immunol. 9:112. PubMed
  106. Guilliams M, et al. 2022. Cell. 185:379. PubMed
  107. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  108. Cepeda JR, et al. 2020. MAbs. 12:1836714. PubMed
  109. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  110. Zhang Z, et al. 2018. Nat Med. 24:617. PubMed
  111. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
  112. Hoffmann FM, et al. 2018. Front Immunol. 9:1046. PubMed
  113. Rebouças A, et al. 2021. Microorganisms. 9:. PubMed
  114. Rigo MM, et al. 2020. FEBS J. :. PubMed
  115. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  116. Wikstrom M, et al. 2006. J Immunol. 177:913. PubMed
  117. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  118. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  119. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  120. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  121. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  122. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  123. Keerthivasan S, et al. 2021. Immunity. 54(7):1511-1526.e8. PubMed
  124. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
  125. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  126. von Roemeling CA, et al. 2020. Nat Commun. 11:1508. PubMed
  127. Cá B, et al. 2019. Front Microbiol. 1.876388889. PubMed
  128. Eisenach P, et al. 2010. J Cell Sci. 123:4182. PubMed
  129. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  130. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  131. García G, et al. 2020. Am J Pathol. 844:190. PubMed
  132. Leppin K, et al. 2014. Invest Ophthalmol Vis Sci . 55:3603. PubMed
  133. Benson M, et al. 2007. J Exp Med. 204:1765. PubMed
  134. Simmons S et al. 2019. Elife. 8 pii: e41239. PubMed
  135. Van Der Zande HJP, et al. 2021. FASEB J. 35:e21331. PubMed
  136. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  137. Goltsev Y et al. 2018. Cell. 174(4):968-981 . PubMed
  138. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
  139. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  140. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  141. Danne C et al. 2017. Cell host & microbe. 22(6):733-745 . PubMed
  142. Chen B, et al. 2021. Cell. 184:6262. PubMed
  143. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  144. Hung LY, et al. 2019. J Immunol. 203:511. PubMed
  145. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  146. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  147. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  148. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  149. Fritz Y, et al. 2017. J Invest Dermatol. 137:696. PubMed
  150. Ito Y, et al. 2018. J Exp Med. 215:2617. PubMed
  151. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  152. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
RRID
AB_313770 (BioLegend Cat. No. 117301)
AB_313771 (BioLegend Cat. No. 117302)

Antigen Details

Structure
Integrin α-chain, associates with integrin β2 (CD18), 150 kD
Distribution

Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells

Function
Cellular adhesion
Ligand/Receptor
iC3b, fibrinogen
Cell Type
Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen Facts Book Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Lopez-Rodriguez C, et al. 1996. J. Immunol. 156:3780.

Gene ID
16411 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD11c
Specificity Alt (DOES NOT SHOW ON TDS):
CD11c
App Abbreviation (DOES NOT SHOW ON TDS):
FC,CyTOF®,IP,IHC
UniProt
View information about CD11c on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD11c Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD11c N418 FC
Biotin anti-mouse CD11c N418 FC,IHC-F
FITC anti-mouse CD11c N418 FC
PE anti-mouse CD11c N418 FC
Purified anti-mouse CD11c N418 FC,CyTOF®,IP,IHC
Alexa Fluor® 488 anti-mouse CD11c N418 FC
Alexa Fluor® 647 anti-mouse CD11c N418 FC,IHC,ICC,3D IHC
PE/Cyanine5 anti-mouse CD11c N418 FC
PE/Cyanine7 anti-mouse CD11c N418 FC
Brilliant Violet 605™ anti-mouse CD11c N418 FC
Alexa Fluor® 700 anti-mouse CD11c N418 FC
Pacific Blue™ anti-mouse CD11c N418 FC
APC/Cyanine7 anti-mouse CD11c N418 FC
PerCP/Cyanine5.5 anti-mouse CD11c N418 FC
PerCP anti-mouse CD11c N418 FC
Brilliant Violet 421™ anti-mouse CD11c N418 FC,IHC
Brilliant Violet 570™ anti-mouse CD11c N418 FC
Brilliant Violet 785™ anti-mouse CD11c N418 FC
Brilliant Violet 510™ anti-mouse CD11c N418 FC
Brilliant Violet 650™ anti-mouse CD11c N418 FC
Purified anti-mouse CD11c (Maxpar® Ready) N418 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD11c N418 IHC-F,3D IHC
PE/Dazzle™ 594 anti-mouse CD11c N418 FC
Brilliant Violet 711™ anti-mouse CD11c N418 FC
APC/Fire™ 750 anti-mouse CD11c N418 FC
TotalSeq™-A0106 anti-mouse CD11c N418 PG
Brilliant Violet 750™ anti-mouse CD11c N418 FC
TotalSeq™-B0106 anti-mouse CD11c N418 PG
TotalSeq™-C0106 anti-mouse CD11c N418 PG
KIRAVIA Blue 520™ anti-mouse CD11c N418 FC
Spark Blue™ 550 anti-mouse CD11c N418 FC
Spark NIR™ 685 anti-mouse CD11c N418 FC
Spark UV™ 387 anti-mouse CD11c N418 FC
Spark Red™ 718 anti-mouse CD11c N418 FC
Spark Blue™ 515 anti-mouse CD11c N418 FC
PerCP/Fire™ 806 anti-mouse CD11c N418 FC
Spark PLUS UV™ 395 anti-mouse CD11c N418 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account